Page 3 - Minor Use News Today

Surplus funds, held by AHDB since the statutory levy for horticulture ended in April 2022, are to be used to secure the future of important work on plant

Extension of Authorisation for Minor Use (EAMU) £1.5m funding 'must be paid for by the Government' - from HortWeek

Diarrhea is also a prevalent side effect in dogs undergoing cancer treatment; managing diarrhea can be important to maintain successful cancer treatment in both humans and dogsSAN FRANCISCO, CA / ACCESSWIRE

Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from FDASAN FRANCISCO, CA / ACCESSWIRE / April 27, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar

Canalevia-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for CID in dogs to receive any type of approval from the FDAVeterinary oncologists

Efforts to fill the void left by AHDB Potatoes have progressed with the website launch of a grower-led organisation of sector stakeholders. AHDB Potatoes

Canalevia-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for CID in dogs to receive any type of approval from the FDAU.S. veterinarians, veterinary

Canalevia™-CA1, which received conditional approval from the FDAon December 21, 2021, is the first and only treatment for CID in dogs to receive any type of approval from the FDA ... | March 1, 2022

In December of 2021, FDA conditionally approved Canalevia-CA1 for treatment of chemotherapy-induced diarrhea in dogs, and the company expects Canalevia could receive FDA conditional approval, under the

Canalevia-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for CID in dogs to receive any type of approval from FDAU.S. veterinarians, veterinary